Home › Funds › Callodine Capital Management, LP › GSK
Callodine Capital Management, LP position in GSK
GSK PLC · Health Care
Callodine Capital Management, LP reported holding 1,047,359 shares of GSK (GSK PLC) in its Q3 2026 13F filing — a position valued at US$50.5M, representing 3.23% of its reported portfolio and ranking #8 among its reported holdings. Callodine Capital Management, LP has disclosed GSK holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Callodine Capital Management, LP's GSK position evolved
Callodine Capital Management, LP first disclosed a stake in GSK in Q3 2023 at 475,000 shares (US$17.2M). The position peaked in Q1 2026 at 1,259,477 shares, worth US$69.5M. Across 13 filings, Callodine Capital Management, LP increased the stake 8 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,047,359 shares valued at US$50.5M — an increase of 67,619 shares quarter over quarter.. Notable position changes include a 35% increase in Q2 2024 (shares rose 6% over the following quarter), a 43% increase in Q4 2025 (shares rose 13% over the following quarter), a 25% increase in Q1 2026 (shares fell 5% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 475.00K | $17.22M | New |
| Q4 2023 | 450.00K | $16.68M | Reduce |
| Q1 2024 | 400.00K | $17.15M | Reduce |
| Q2 2024 | 540.00K | $20.79M | Add |
| Q3 2024 | 605.00K | $24.73M | Add |
| Q4 2024 | 700.00K | $23.67M | Add |
| Q1 2025 | 570.00K | $22.08M | Reduce |
| Q2 2025 | 598.52K | $22.98M | Add |
| Q3 2025 | 702.05K | $30.30M | Add |
| Q4 2025 | 1.00M | $49.25M | Add |
| Q1 2026 | 1.26M | $69.51M | Add |
| Q2 2026 | 979.74K | $51.36M | Reduce |
| Q3 2026 | 1.05M | $50.45M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GSK and 13F data
GSK (GSK PLC) is a Health Care company. 20 other funds we track also report a position in GSK — the largest reported positions include Dodge & Cox (US$2.53B), DODGE & COX (US$2.53B), PRIMECAP MANAGEMENT CO/CA/ (US$1.21B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GSK
- Dodge & Cox 48.20M sh · $2.53B · Q2 2026
- DODGE & COX 48.20M sh · $2.53B · Q2 2026
- PRIMECAP MANAGEMENT CO/CA/ 25.19M sh · $1.21B · Q3 2026
- JTC Employer Solutions Trustee Ltd 8.08M sh · $389.17M · Q3 2026
- Mondrian Investment Partners LTD 4.97M sh · $239.21M · Q3 2026
- Grantham, Mayo, Van Otterloo & Co. LLC 3.92M sh · $188.73M · Q3 2026
- EQUITY INVESTMENT CORP 3.56M sh · $171.52M · Q3 2026
More on Callodine Capital Management, LP
FAQ
How long has Callodine Capital Management, LP held GSK?
Callodine Capital Management, LP has disclosed GSK holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Callodine Capital Management, LP's current position in GSK?
As of Q3 2026, Callodine Capital Management, LP holds 1.05M shares of GSK (GSK PLC), valued at $50.45M, representing 3.23% of its reported portfolio and ranking #8.
Has Callodine Capital Management, LP been buying or selling GSK?
In the latest 13F filing (Q3 2026), Callodine Capital Management, LP increased its position in GSK. The position peaked in Q1 2026 at 1.26M shares.
Which other funds hold GSK?
Other major institutional holders of GSK include Dodge & Cox, DODGE & COX, PRIMECAP MANAGEMENT CO/CA/, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.